Table 3.

Neuropsychological tests performance before and after DTG by EFV use at pre-switch

	EFV-based ART	Non-EFV-based ART	p-value	EFV-based ART	Non-EFV-based ART	p-value
NPZ-4	0.69 (0.32 to 1.10)	0.83 (0.27 to 1.14)	0.776	0.87 (0.37 to 1.19)	0.89 (0.31 to 1.21)	0.747
zCT1	1.13 (0.59 to 1.54)	1.25 (0.53 to 1.63)	0.667	1.29 (0.63 to 1.74)	1.36 (0.89 to 1.81)	0.689
zCT2	0.59 (0.12–1.10)	0.65 (0.26 to 1.15)	0.525	0.86 (0.40 to 1.20)	0.81 (0.17 to 1.33)	0.916
zGPB	0.55 (− 0.15 to 1.07)	0.44 (− 0.40 to 1.00)	0.379	0.66 (− 0.08 to 1.14)	0.56 (− 0.45 to 1.04)	0.857
zTrailA	0.75 (0.09 to 1.15)	0.79 (0.37 to 1.13)	0.902	0.84 (0.11 to 1.37)	0.65 (− 0.21 to 1.15)	0.126

Median (IQR) is presented

ART antiretroviral therapy; EFV Efavirenz, NPZ-4 composite z-score of the 4 neuropsychiatric tests, CT1 Color Trails 1, CT2 Color Trails 2, GPB grooved pegboard test, TrailA trail making A